SOURCE: Gene Express, Inc.

October 19, 2007 09:58 ET

Gene Express's David Lester, Ph.D. Featured as Keynote Speaker in Webinar Titled "Innovations in Clinical Trials: The Clinical Trial of the Future"

TOLEDO, OH--(Marketwire - October 19, 2007) - Gene Express, Inc. today announced that David Lester, Ph.D., Senior Vice President of Strategy and Corporate Development, will be the keynote speaker for a web seminar hosted by the Institute for International Research (IIR), titled "Innovations in Clinical Trials: The Clinical Trial of the Future," on October 24, 2007, beginning at 1:00 pm ET.

Dr. Lester will discuss the current clinical trial environment and challenges such as recruitment and drop out rates, which drive increased costs, and extended duration of trials. He will share some innovative approaches to developing a radically different clinical trial template that would provide an overall enhanced patient-experience and make subjects more interested in enrolling as well as establish conditions by which therapeutic intervention could be used once approved and in clinical practice.

To register for the free web seminar, please visit:

David S. Lester received his Ph.D. in Biological Sciences from Northwestern University and has held positions at Harvard University Medical School, the Weizmann Institute of Science (Israel) and National Institute of Neurological Disorders and Stroke at the National Institute of Health. He is currently serving as Senior Vice President at Gene Express, Inc. in charge of Strategy and Corporate Development. Dr. Lester is also President of Innovative Technologies for Health and Wellness (ITHW, Inc.). He has held executive positions, and played pivotal roles at Pfizer, in the Global Clinical Technology and Human Health Technologies Groups, as well as at Pharmacia Corp., and at the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA).

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug and molecular diagnostic development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information

  • Contact:
    Rachel Levine
    The Global Consulting Group
    Tel: 646-284-9439